Search articles in News

Filter Articles

Open filters

Sections

Found 2,566 articles

Robert S. Langer, Co-Founder of Moderna, Joins Lindus Health's Advisory Board
- 31 Jan 2024
- Editor
Lindus Health, an anti-CRO running radically faster, more reliable clinical trials for life science pioneers, has announced the appointment of Professor Robert S. Langer, renowned scientist, Institute Professor at Massachusetts Institute of Technology (MIT), and co-founder of Moderna, Inc. to its Advisory Board.
Huxley Health Inc. Provides Corporate Update - Appoints Bruce Linton as Chairman
- 31 Jan 2024
- Editor
Huxley Health Inc. (“Huxley” or the “Company”) is pleased to provide you with a comprehensive corporate update, highlighting significant milestones and developments that have shaped Huxley over the past year.
Boom in life science recruitment leads to ARx expansion plans
- 29 Jan 2024
- Editor
ARx, a leading brand in Life Science recruitment services internationally. Coming off the back of a huge year for the company, has entered into their “season of growth” and are creating a whole new team.
PharmiWeb Unveils New Branding in Celebration of 25th Anniversary
- 29 Jan 2024
- Lucy Walters
PharmiWeb, the leading global life science news and jobs portal, is excited to unveil its new branding in line with the company’s 25th anniversary celebrations. This fresh visual identity symbolises PharmiWeb’s commitment to continuous evolution, and to creating a standout user experience for both candidates and clients, whilst still paying homage to the company’s origins.
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After Surgery
- 29 Jan 2024
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 AMBASSADOR (A031501)/KEYNOTE-123 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, for the adjuvant treatment of high-risk patients with localized muscle-invasive urothelial carcinoma (MIUC) and locally advanced resectable urothelial carcinoma.
Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy
- 29 Jan 2024
- Editor
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 KEYNOTE-564 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
Subcutaneous Nivolumab (nivolumab and hyaluronidase) Shows Noninferiority Compared to Intravenous Opdivo (nivolumab) in Advanced or Metastatic Clear Cell Renal Cell Carcinoma in CheckMate -67T Trial
- 29 Jan 2024
- Editor
Bristol Myers Squibb (NYSE: BMY) today announced the first disclosure of data from the Phase 3 CheckMate -67T trial, evaluating the subcutaneous formulation of Opdivo (nivolumab) co-formulated with Halozyme’s proprietary recombinant human hyaluronidase (rHuPH20) (herein referred to as “subcutaneous nivolumab”) compared to intravenous (IV) Opdivo in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC).
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel)in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
- 29 Jan 2024
- Editor
Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization approval of Abecma® (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody.
European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
- 29 Jan 2024
- Editor
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, “Astellas”) today announced that on January 26 the European Medicines Agency (EMA) validated for review a Type II variation application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) as a combination therapy for the first-line treatment of adult patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC).
European Commission authorises GSK’s Omjjara (momelotinib)
- 29 Jan 2024
- Editor
GSK plc (LSE/NYSE: GSK) today announced the European Commission* granted marketing authorisation for Omjjara (momelotinib), a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor.
GSK’s RSV vaccine, Arexvy, accepted for regulatory review by the European Medicines Agency for the prevention of RSV disease in adults aged 50-59 at increased risk
- 29 Jan 2024
- Editor
GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted the company’s regulatory application to expand the use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine to adults aged 50-59 who are at increased risk for RSV disease.
Robert S. Langer, Co-Founder of Moderna, Joins Lindus Health’s Advisory Board
- 25 Jan 2024
- Editor
Lindus Health, an anti-CRO running radically faster, more reliable clinical trials for life science pioneers, is announcing the appointment of Professor Robert S. Langer, renowned scientist, Institute Professor at Massachusetts Institute of Technology (MIT), and co-founder of Moderna, Inc. to its Advisory Board.
International life sciences marketing agency announces strategic rebrand
- 25 Jan 2024
- Editor
The move is a strategic response to the evolving landscape of post-COVID pharmaceutical and biotech marketing requirements, demonstrating a commitment to align more closely with client challenges and their commercial needs.
Catharina Nordlund is appointed Global Head of HR for BICO Group AB (publ)
- 25 Jan 2024
- Editor
BICO Group AB today announces the appointment of Catharina Nordlund as Global Head of HR. The role will further strengthen the Executive Management and be responsible for shaping and executing BICO’s global HR strategy in order to build a people and high-performance culture.
Top 10 Pharma and Biotech Companies in Germany 2024
- 25 Jan 2024
- Lucy Walters
The country is home to more than 600 pharmaceutical companies, with the pharma industry employing around 140,000 people. In this article, we highlight the top 10 biotech and pharma companies in Germany as of 2023, based on their market capitalisation.
Cytomos appoints new Chief Commercial and Innovation Officer and Techno-Commercial Adviser: Driving the commercialisation strategy as the company evolves from an R&D to a product-based business
- 24 Jan 2024
- Editor
TechBio company, Cytomos (www.cytomotos.com) is pleased to announce the appointment of Dr Fernanda Masri as Chief Commercial and Innovation Officer and Dr Christel Fenge as Techno-Commercial Adviser. In her new role, Fernanda will spearhead Cytomos’ commercialisation strategy, as the company rapidly evolves the technology into a commercial product platform suitable from early R&D and Product Development through to manufacturing, building on the progress over the past decade.
Eckert & Ziegler and Full-Life Technologies Sign Actinium-225 Supply Agreement for Next Generation Radiopharmaceuticals
- 24 Jan 2024
- Editor
Eckert & Ziegler (ISIN DE0005659700, SDAX) and Full-Life Technologies (Full-Life), a clinical stage, fully integrated global radiotherapeutics company today announced they have entered into an agreement for the supply of Actinium-225 (Ac-225). The agreement provides Full-Life with access to Eckert & Ziegler's high-purity Actinium-225, a radionuclide for use in developing the next generation of therapeutic radiopharmaceuticals.
Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting
- 24 Jan 2024
- Editor
Akouos, Inc., a wholly owned subsidiary of Eli Lilly and Company (NYSE: LLY), today announced positive initial clinical results from the Phase 1/2 AK-OTOF-101 study, which demonstrated pharmacologic hearing restoration within 30 days of AK-OTOF administration in the first participant, an individual with a decade-plus history of profound hearing loss.
The Future of Biotech Talent Acquisition: Trends and Predictions for 2024
- 23 Jan 2024
- Lucy Walters
The global biotechnology market was estimated at $1.37 trillion in 2022, with an expected compound annual growth rate of 13.96% between 2023 and 2030. As the industry continues to evolve at an unprecedented rate, talent acquisition professionals within the life science industry face unique challenges when it comes to attracting and retaining the top talent needed to propel this growth.
RApport Global Acquired by ELIQUENT Life Sciences
- 22 Jan 2024
- Editor
ELIQUENT Life Sciences (ELIQUENT), a global regulatory consulting firm for the life sciences industry, today announced the acquisition of RApport Global Strategic Services (RApport). RApport is a UK based international regulatory consultancy supporting life science innovators gaining and maintaining authorization for products worldwide. ELIQUENT’s acquisition of RApport represents an important step in the company’s international growth and expanded European capabilities.